Vimarsana
Biggest News Aggregation in the World

Orexin Agonist Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Orexin Agonist Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Orexin Agonist Program Today - Breaking & Trending Today

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 - Vimarsana News

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Published: March 28, 2024

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist...

Source: marketscreener.com
Related Topics:
City OfUnited KingdomUnited StatesKristenk SheppardCentessa PharmaceuticalsTechnology PlatformOrexin Agonist ProgramDrug AdministrationLockbody Technology PlatformResearch Development ExpensesEuropean Association For HaemophiliaExchange CommissionUpcoming Program MilestonesAmerican Society Of HematologyHemophilia ProgramAgonist ProgramOngoing PhaseSaurabh SahaChief Executive OfficerAmerican SocietyAnnual MeetingAnnual CongressEuropean AssociationAllied DisordersInvestigational New Drug
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders -October 25, 2023 at 08:00 am EDT - Vimarsana News

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders -October 25, 2023 at 08:00 am EDT

Published: October 25, 2023

- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 - ORX750 advancing in IND-enabling studies; Clinical proof...

Source: marketscreener.com
Related Topics:
United StatesCity OfUnited KingdomRio De JaneiroEstado Do RioOrexin AtaxinKristenk SheppardMario Alberto AccardiWorld Sleep CongressCentessa Orexin Agonist ProgramExchange CommissionCentessa PharmaceuticalsEu PressNarcolepsy TypeWurts Black PhdOrexin Agonist ProgramOral Selective Orexin ReceptorPromotes WakefulnessReduces CataplexySleep CongressAlberto Accardi PhdOrexin AgonistChief Executive OfficerWorld SleepAnnual Report